Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Laurence David‐Boudet"'
Autor:
Antonin Bouroumeau, Lucile Bussot, Thierry Bonnefoix, Cyril Fournier, Caroline Chapusot, Olivier Casasnovas, Laurent Martin, Anne McLeer, Edwige Col, Laurence David‐Boudet, Christine Lefebvre, Caroline Algrin, Tatiana Raskovalova, Marie‐Christine Jacob, Claire Vettier, Simon Chevalier, Mary B Callanan, Rémy Gressin, Anouk Emadali, Hervé Sartelet
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 7, Iss 6, Pp 604-615 (2021)
Abstract Diffuse large B‐cell lymphoma (DLBCL) is a clinically heterogeneous entity, in which the first‐line treatment currently consists of an immuno‐chemotherapy regimen (R‐CHOP). However, around 30% of patients will not respond or will rel
Externí odkaz:
https://doaj.org/article/5db1d304fd2549028c3657336d17a691
Autor:
Antonin Bouroumeau, Lucile Bussot, Hervé Sartelet, Cyril Fournier, Patricia Betton-Fraisse, Edwige Col, Laurence David-Boudet, Anne McLeer, Christine Lefebvre, Tatiana Raskovalova, Marie-Christine Jacob, Claire Vettier, Simon Chevalier, Caroline Algrin, Sylvain Carras, Rémy Gressin, Mary B. Callanan, Thierry Bonnefoix, Anouk Emadali
Publikováno v:
HemaSphere, Vol 5, Iss 7, p e598 (2021)
Externí odkaz:
https://doaj.org/article/8ac64ed56f51444faed1b51882590f5c
Autor:
Antonin Bouroumeau, Lucile Bussot, Sieme Hamaidia, Andrea Garcìa-Sandoval, Anna Bergan-Dahl, Patricia Betton-Fraisse, Samuel Duley, Cyril Fournier, Romain Aucagne, Annie Adrait, Yohann Couté, Anne McLeer, Edwige Col, Laurence David-Boudet, Tatiana Raskovalova, Marie-Christine Jacob, Claire Vettier, Simon Chevalier, Sylvain Carras, Christine Lefebvre, Caroline Algrin, Rémy Gressin, Mary B. Callanan, Hervé Sartelet, Thierry Bonnefoix, Anouk Emadali
Publikováno v:
Cancers, Vol 13, Iss 23, p 5900 (2021)
R-CHOP immuno-chemotherapy significantly improved clinical management of diffuse large B-cell lymphoma (DLBCL). However, 30–40% of DLBCL patients still present a refractory disease or relapse. Most of the prognostic markers identified to date fail
Externí odkaz:
https://doaj.org/article/42f7234b631441eaabdf3f156bce694c
Autor:
Lucile Bussot, Simon Chevalier, Caroline Algrin, Anouk Emadali, Laurence David-Boudet, Christine Lefebvre, Cyril Fournier, Laurent Martin, Claire Vettier, O. Casasnovas, Remy Gressin, Caroline Chapusot, Mary Callanan, Edwige Col, Thierry Bonnefoix, Marie-Christine Jacob, Anne McLeer, Antonin Bouroumeau, Tatiana Raskovalova, Hervé Sartelet
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 7, Iss 6, Pp 604-615 (2021)
The Journal of Pathology: Clinical Research
The Journal of Pathology: Clinical Research
Diffuse large B‐cell lymphoma (DLBCL) is a clinically heterogeneous entity, in which the first‐line treatment currently consists of an immuno‐chemotherapy regimen (R‐CHOP). However, around 30% of patients will not respond or will relapse. Ove
Autor:
Tatiana Raskovalova, Edwige Col, Caroline Algrin, Marie-Christine Jacob, Cyril Fournier, Anne McLeer, Anouk Emadali, Samuel Duley, Romain Aucagne, Antonin Bouroumeau, Mary Callanan, Claire Vettier, Hervé Sartelet, Christine Lefebvre, Patricia Betton-Fraisse, Thierry Bonnefoix, Yohann Couté, Lucile Bussot, Andrea Garcìa-Sandoval, Sieme Hamaidia, Annie Adrait, Simon Chevalier, Laurence David-Boudet, Anna Bergan-Dahl, Remy Gressin, Sylvain Carras
Publikováno v:
Cancers
Cancers, 2021, 13 (23), pp.5900. ⟨10.3390/cancers13235900⟩
Cancers, Vol 13, Iss 5900, p 5900 (2021)
Cancers; Volume 13; Issue 23; Pages: 5900
Cancers, 2021, 13 (23), pp.5900. ⟨10.3390/cancers13235900⟩
Cancers, Vol 13, Iss 5900, p 5900 (2021)
Cancers; Volume 13; Issue 23; Pages: 5900
Simple Summary CYCLON is a nuclear protein, which has been associated with disease progression and treatment resistance in DLBCL, the most common form of aggressive B-cell lymphoma, but also represents a predictive factor of refractory disease and re
Autor:
Laetitia Vanwonterghem, Jean-Luc Coll, Beatrice Eymin, Marie Guerard, Laurence David-Boudet, Sylvie Gazzeri, P. Perron, Anne-Sophie Hatat, Amandine Hurbin, Thomas Robin, Benoit Busser, Sylvie Lantuejoul
Publikováno v:
Cancer Letters
Cancer Letters, 2018, 420, pp.146-155. ⟨10.1016/j.canlet.2018.01.080⟩
Cancer Letters, Elsevier, 2018, 420, pp.146-155. ⟨10.1016/j.canlet.2018.01.080⟩
Cancer Letters, 2018, 420, pp.146-155. ⟨10.1016/j.canlet.2018.01.080⟩
Cancer Letters, Elsevier, 2018, 420, pp.146-155. ⟨10.1016/j.canlet.2018.01.080⟩
International audience; Many Receptor Tyrosine Kinases translocate from the cell surface to the nucleus in normal and pathological conditions, including cancer. Here we report the nuclear expression of insulin-like growth factor-1 receptor (IGF1R) in
Autor:
Laurence David-Boudet, Serge Lebecque, Christelle Combaz-Lair, Sylvie Lantuejoul, Nolwenn Le Stang, Anne McLeer-Florin, Françoise Galateau-Sallé, Gilbert Ferretti, Mickael Duruisseaux, Elisabeth Brambilla
Publikováno v:
Human Pathology
Human Pathology, WB Saunders, 2016, 52, pp.9-18. ⟨10.1016/j.humpath.2016.01.010⟩
Human Pathology, WB Saunders, 2016, 52, pp.9-18. ⟨10.1016/j.humpath.2016.01.010⟩
International audience; Malignant pleural mesothelioma (MPM) is an aggressive tumor with no effective therapy. However PD-L1/PD-1 immunity checkpoint therapies gave encouraging results; TLR3 is a programmed death factor, which triggering up-regulates
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9a488cf1ba9927933fea9114c03b322
https://hal.archives-ouvertes.fr/hal-01792622
https://hal.archives-ouvertes.fr/hal-01792622
Autor:
Caroline Roelants, Pierre Champelovier, Mathieu Laramas, Claude Cochet, Eve Duchemin-Pelletier, Jean Boutonnat, Benoit Bestgen, Anne McLeer-Florin, Sofia Giacosa, Céline Tisseyre, Pasquier D, Laurence David-Boudet, Odile Filhol, Catherine Pillet, Maysoun Kassem, Laure Schoutteten, Jean-Jacques Rambeaud, Cédric Aubert, Jean Luc Descotes, Valentin Arnoux, Jean-Alexandre Long
Publikováno v:
Protein Kinase CK2 Cellular Function in Normal and Disease States ISBN: 9783319145433
Renal cell carcinomas (RCCs) have notoriously been shown to be refractory to traditional therapies including radiation and cytokine therapies. The use of molecularly targeted therapies against mTOR, VEGF, and other angiogenic factors has significantl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::605a19671482a68192b4435e3a2c7138
https://doi.org/10.1007/978-3-319-14544-0_14
https://doi.org/10.1007/978-3-319-14544-0_14